Days Inventory is also known as Days Sales of Inventory (DSI). SCYNEXIS's Average Total Inventories for the
three
months ended in Mar. 2025 was $0.00 Mil. SCYNEXIS's Cost of Goods Sold for the
three
months ended in Mar. 2025 was $0.00 Mil.
The historical rank and industry rank for SCYNEXIS's Days Inventory or its related term are showing as below:
During the past 13 years, SCYNEXIS's highest Days Inventory was 541.65. The lowest was 21.00. And the median was 395.80.
SCYX's Days Inventory is not ranked *
in the Drug Manufacturers industry.
Industry Median: 161.42 * Ranked among companies with meaningful Days Inventory only.
SCYNEXIS's Days Inventory
stayed the same
from Mar. 2024 (0.00) to Mar. 2025 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SCYNEXIS's Inventory-to-Revenue for the
three
months ended in Mar. 2025 was 0.00.
SCYNEXIS Days Inventory Historical Data
The historical data trend for SCYNEXIS's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SCYNEXIS's Days Inventory
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's Days Inventory Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Days Inventory distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (NAS:SCYX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
SCYNEXIS's Inventory Turnover for the
three
months ended in Mar. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SCYNEXIS's Inventory to Revenue for the
three
months ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
SCYNEXIS Days Inventory Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 